Heart failure & cardiomyopathies
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF Trial
Authors' conclusion
Compared to treatment with Val in patients with worsening HF and LVEF >40%, treatment with Sac/Val is associated with greater clinical benefit in those with LVEF ≤60% than in those with LVEF >60%.
Study context
- Population
- Patients stabilised after worsening heart failure (HF) with left ventricular ejection fraction (LVEF) >40%, by baseline LVEF ≤60% vs >60%
- Comparison
- Sac/valsartan (Val) vs Val, by LVEF ≤60% vs >60%
- Primary endpoint
- Recurrent composite events:
- Adjudicated CV death
- HF hospitalizations
- Urgent HF visits
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
Recurrent composite events, by LVEF subgroup
Sac/Val vs ValEstimate (95% CI)P value
LVEF ≤60%; predominantly driven by HF hospitalizations
rate ratio 0.60(0.37–0.99)
P = 0.046LVEF >60%
RR 1.46(0.77–2.79)
P = 0.24Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Symptomatic hypotension, by LVEF subgroupSac/Valvs ValLVEF >60% | 3.55 (1.35–9.37) | P = 0.01 | |
| Symptomatic hypotension, by LVEF subgroupSac/Valvs ValLVEF ≤60% | 1.36 (0.79–2.32) | P = 0.27 | |
| 0.10.31310Odds ratio (log scale) |
- Symptomatic hypotension, by LVEF subgroup: interaction P-value .09
Original publication
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF Trial. Am Heart J. Published 21 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →